Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy (opens in new tab)

Trial suggests patients with a low test score could be treated with hormone therapy alone with near-identical outcomes Millions of women with breast cancer could be spared chemotherapy with a groundbreaking genomic test, according to the results of a trial that could transform healthcare guidelines worldwide., the world’s most prevalent form of the disease, involves surgery to remove tumours. Chemotherapy is then usually recommended when doctors believe there is a risk the disease will return.